SI-BONE, Inc. to Announce Q4 and Full Year 2025 Financial Results on February 23, 2026

SI-BONE will report Q4 and 2025 financial results on February 23, 2026, followed by a conference call.

Quiver AI Summary

SI-BONE, Inc., a leader in procedural solutions for compromised bone, announced that it will release its financial results for the fourth quarter and full year ending December 31, 2025, on February 23, 2026, after market close. Following the release, management will host a conference call at 1:30 PM PT. Investors can access the conference by registering online or listening to a live webcast available on the company's website. SI-BONE specializes in applications related to SI joint fusion, adult spinal deformity, and pelvic trauma, with over 140,000 procedures performed since 2009, supported by substantial clinical evidence. For further details, visit their website or contact them directly.

Potential Positives

SI-BONE will report its fourth quarter and full year financial results, providing transparency and updates to investors about the company's performance.
The upcoming conference call presents an opportunity for investors to engage directly with management, fostering communication and shareholder relations.
SI-BONE's standing as the global leader in developing procedural solutions for compromised bone is underscored by its extensive clinical evidence and significant operational history, enhancing its credibility in the healthcare market.

Potential Negatives

Failure to provide preliminary financial guidance or expectations for future performance may lead to investor uncertainty and lack of confidence in the company's direction.
Announcing the financial results after market close can sometimes be interpreted negatively if the market reacts poorly after the earnings announcement, particularly if there are worries about the company’s future profitability.
None

FAQ

When will SI-BONE announce its financial results?

SI-BONE will report its financial results for the fourth quarter and full year on February 23, 2026, after market close.

How can I listen to the SI-BONE conference call?

Investors can listen to the conference call by registering at https://edge.media-server.com/mmc/p/zfxy6yox.

Where can I find the SI-BONE webcast archive?

The webcast will be available for replay for at least 90 days on the "Investors" section of SI-BONE's website.

What is the focus of SI-BONE, Inc.?

SI-BONE is focused on developing procedural solutions for clinical challenges related to compromised bone.

How many procedures has SI-BONE supported since 2009?

SI-BONE has supported physicians in performing over 140,000 procedures since its inception in 2009.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$SIBN Insider Trading Activity

$SIBN insiders have traded $SIBN stock on the open market 51 times in the past 6 months. Of those trades, 0 have been purchases and 51 have been sales.

Here’s a breakdown of recent trading of $SIBN stock by insiders over the last 6 months:

JEFFREY W DUNN has made 0 purchases and 7 sales selling 120,586 shares for an estimated $2,337,528.
ANSHUL MAHESHWARI (Chief Financial Officer) has made 0 purchases and 13 sales selling 37,904 shares for an estimated $711,142.
MICHAEL A. PISETSKY (SVP, Ops & Adm/Chief Legal Ofr) has made 0 purchases and 12 sales selling 33,245 shares for an estimated $625,395.
LAURA FRANCIS (Chief Executive Officer) has made 0 purchases and 10 sales selling 33,506 shares for an estimated $562,631.
ANTHONY J RECUPERO (President, Commercial Ops) has made 0 purchases and 8 sales selling 14,654 shares for an estimated $246,048.
JOHN GORDON FREUND sold 12,132 shares for an estimated $193,997

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$SIBN Revenue

$SIBN had revenues of $48.7M in Q3 2025. This is an increase of 20.61% from the same period in the prior year.

You can track SIBN financials on Quiver Quantitative's SIBN stock page.

$SIBN Hedge Fund Activity

We have seen 93 institutional investors add shares of $SIBN stock to their portfolio, and 81 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

CADIAN CAPITAL MANAGEMENT, LP added 595,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $8,758,400
HOLOCENE ADVISORS, LP removed 585,311 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $8,615,777
POINT72 (DIFC) LTD added 581,695 shares (+19887.0%) to their portfolio in Q3 2025, for an estimated $8,562,550
AMERICAN CENTURY COMPANIES INC added 521,683 shares (+22.5%) to their portfolio in Q3 2025, for an estimated $7,679,173
WELLINGTON MANAGEMENT GROUP LLP added 364,897 shares (+74.7%) to their portfolio in Q3 2025, for an estimated $5,371,283
POINT72 ASSET MANAGEMENT, L.P. added 251,102 shares (+100.1%) to their portfolio in Q3 2025, for an estimated $3,696,221
MARSHALL WACE, LLP removed 243,933 shares (-55.9%) from their portfolio in Q3 2025, for an estimated $3,590,693

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$SIBN Analyst Ratings

Wall Street analysts have issued reports on $SIBN in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Truist Securities issued a "Buy" rating on 12/18/2025
Needham issued a "Buy" rating on 12/16/2025

To track analyst ratings and price targets for $SIBN, check out Quiver Quantitative's $SIBN forecast page.

$SIBN Price Targets

Multiple analysts have issued price targets for $SIBN recently. We have seen 5 analysts offer price targets for $SIBN in the last 6 months, with a median target of $23.0.

Here are some recent targets:

Mathew Blackman from TD Cowen set a target price of $21.0 on 01/27/2026
David Rescott from Truist Securities set a target price of $23.0 on 12/18/2025
Caitlin Roberts from Canaccord Genuity set a target price of $27.0 on 12/17/2025
David Saxon from Needham set a target price of $27.0 on 12/16/2025
Drew Ranieri from Morgan Stanley set a target price of $23.0 on 12/02/2025

Full Release

SANTA CLARA, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced it will report financial results for the fourth quarter and full year ended December 31, 2025 after market close on Monday, February 23, 2026. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p/zfxy6yox . Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com . The webcast will be archived and available for replay for at least 90 days after the event.

About SI-BONE, Inc.

SI-BONE (NASDAQ: SIBN) is the global leader in developing procedural solutions to address clinical challenges associated with compromised bone. SI-BONE's expertise in additive manufacturing has resulted in a technology platform with market-leading applications in SI joint fusion, adult spinal deformity and pelvic trauma. Since 2009, SI-BONE has supported physicians in performing a total of over 140,000 procedures. A unique body of clinical evidence supports the use of SI-BONE’s technologies, including four randomized controlled trials and over 200 peer reviewed publications.

For additional information on the company or the products, including risks and benefits, please visit www.si-bone.com .

[email protected]
650-271-7515